Is Non-Responder the best Imputation Methodi in Equivalence Trials?

In this webinar, Dr. Couch will present results from a recent study of multigene hereditary cancer panel testing in >10,000 women with triple-negative breast cancer (TNBC), focusing on the prevalence of cancer gene mutations among TNBC cases along with gene-specific associations with TNBC among Caucasians and African Americans. Clinical implications of these findings will also be discussed.

To slow or reverse the effects of climate change, there is promise in development of biotechnology innovations that enhance the adaptation, resilience, preservation, and restoration of natural and managed ecosystems.

Cell therapy development programs generate encouraging pre-clinical and clinical results with the promise that these tailored therapeutics can provide a curative rather than maintenance therapy. Therapies are being developed across the spectrum from academic institutions to small and medium biotechs/biopharma as well as large pharma companies which have all invested significantly in the cell and gene therapy (CGT) field. As additional CGT therapies gain approval, specifically in solid tumors and auto-immunity, the addressable patient populations will grow requiring scaled -out/-up commercial manufacturing. Although the CGT field is experiencing significant tailwinds, challenges remain. Cell sourcing has long been considered a pain-point which is potentially compounded with the necessity to develop robust GMP manufacturing processes and appropriate analytical methods.

DNA defines who we are. And like anything else, sometimes there are mistakes – mutations in genes that can cause life-lasting conditions. But what if broken genes could be repaired? How many patients could we help in the years ahead? This is the promise and possibility of genome editing.